Lineage Cell Therapeutics Inc. — Director's Dealing 2017

Jul 6, 2017

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

* 1. Name and Address of Reporting Person FARRELL STEPHEN C						2. Issuer Name and Ticker or Trading Symbol BIOTIME INC [ BTX ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 07/01/2017									X Director below)	Officer (give title		10% Owner Other (specify below)
3021 NE 23 COURT					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)
(Street) FORT FL LAUDERDALE			33305											X Person	Form filed by One Reporting Person Form filed by More than One Reporting
(City)		(State)	(Zip)
									Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		and 5)	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4				5. Amount of Securities Beneficially Owned		6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership
									Code	V	Amount		(A) or (D)	Price		Following Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	(Instr. 4)
	Common Shares, no par vaule															97,450		D
									Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any	(Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Form: Direct (D) (I) (Instr. 4)	Ownership or Indirect	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code		V (A)	(D)	Date Exercisable		Expiration Date	Title	or of	Amount Number Shares
Option to Purchase Common Shares	\$3.15	07/01/2017			A		20,000		(1)		06/30/2022	Common Shares		20,000	\$0.00	20,000		D
Option to Purchase Common Shares	\$2.72								(2)		06/30/2021	Common Shares		20,000		20,000		D
Option to Purchase Common Shares	\$3.57								(3)		06/30/2020	Common Shares		20,000		20,000		D
Option to Purchase Common Shares	\$3.11								(4)		06/30/2019	Common Shares		20,000		20,000		D
Option to Purchase Common Shares	\$4.13								(5)		06/30/2018	Common Shares		20,000		20,000		D
Option to Purchase Common Shares	\$4.12								(6)		03/10/2018	Common Shares		20,000		20,000		D

Explanation of Responses:

1. Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.

2. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.

3. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.

4. 1. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
5. 1. Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.
6. 1. Became exercisable in four equal quarterly installments after the date of grant on March 11, 2013.

Remarks:

/s/Stephen C. Farrell 07/05/2017

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.